• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ault Global Holdings Reports Third Quarter 2021 Results

    11/19/21 5:20:00 PM ET
    $ALZN
    $DPW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Capital Goods
    Get the next $ALZN alert in real time by email

    Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the three and nine months ended September 30, 2021.

    Nine months ended September 30, 2021 highlights:

    • Revenue of $44.6 million, an increase of 167% from $16.7 million in the prior nine-month period;
    • Revenue from lending and trading activities of $19.6 million due to the allocation of capital to DP Lending;
    • Revenues from our trading activities during the nine months ended September 30, 2021 included significant net gains on equity securities, including unrealized gains and losses from market price changes. These gains and losses have caused and will continue to cause, significant volatility in our periodic earnings.
    • Revenue from lending and trading activities includes an approximate $6.4 million unrealized gain from the Company's investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders;
    • Revenue from cryptocurrency mining of $693,000 as the Company resumed cryptocurrency mining operations during March 2021; and
    • Net income of $1.3 million compared to a net loss of $24.7 million in the prior nine-month period.

    Three months ended September 30, 2021 highlights:

    • Revenue decreased $36.5 million to negative $30.8 million from positive revenue of $5.7 million in the prior third fiscal quarter;
    • Revenue from lending and trading activities includes unrealized gains and losses and, due to stock price volatility, can result in the Company reporting negative revenue. For the three months ended September 30, 2021, the Company reported negative revenue from lending and trading activities of $(38.9) million, including a $(33.4) million unrealized loss from the Company's investment in Alzamend;
    • Revenue from cryptocurrency mining of $272,000 as the Company resumed cryptocurrency mining operations during March 2021;
    • Net loss of $42.9 million for the quarter;
    • Positive working capital of $93.9 million;
    • Total assets of $225.7 million; and
    • Cash of $44.0 million, marketable securities of $49.9 million and other investments of $62.6 million as of September 30, 2021.

    Revenues

    Revenues by segment for the three months ended September 30, 2021 and 2020 were as follows:

    For the Three Months Ended

    September 30,

    Increase

    2021

     

    2020

     

    (Decrease)

     

    %

     

    Gresham Worldwide

    $ 6,373,000

     

    $ 4,329,000

     

    $ 2,044,000

     

    47%

    TurnOnGreen

    1,094,000

    1,376,000

    (282,000)

    -20%

    Ault Alliance:

     

     

     

     

     

     

     

    Revenue, cryptocurrency mining

    238,000

    -

    238,000

    —

    Revenue, lending and trading activities

    (38,868,000)

     

    (29,000)

     

    (38,839,000)

     

    133,928%

    Other

    369,000

    —

    369,000

    —

    Total revenue

    $ (30,794,000)

     

    $ 5,676,000

     

    $(36,470,000)

     

    -643%

    Gresham Worldwide ("GWW")

    GWW revenues increased by $2.0 million, or 47%, to $6.4 million for the three months ended September 30, 2021, from $4.3 million for the three months ended September 30, 2020. GWW revenue in 2021 includes $1.8 million from Relec, which was acquired on November 30, 2020. In the prior year period, revenue was constrained by working capital issues. The increase in revenue from our GWW segment for customized solutions for the military markets reflects the benefit of our improved liquidity in 2021, as we were able to allocate additional funds to our defense business to improve their ability to fulfill backlog.

    TurnOnGreen

    TurnOnGreen revenues decreased by $282,000 or 20%, to $1.1 million for the three months ended September 30, 2021, from $1.4 million for three months ended September 30, 2020. The decrease is primarily attributable to supply chain disruptions during the quarter.

    Ault Alliance

    Revenues from our cryptocurrency mining operations were $238,000 for the three months ended September 30, 2021, compared to nil for the three months ended September 30, 2020, as we resumed our cryptocurrency mining operations during the first quarter of 2021. Our decision to resume cryptocurrency mining operations in 2021 was based on several factors, which had positively affected the number of active miners we operated, including the market prices of digital currencies, and favorable power costs available at our Michigan data center.

    Revenues from our lending and trading activities decreased to a loss position of $(38.9) million for the three months ended September 30, 2021, from negative revenues of $(29,000) for the three months ended September 30, 2020. Revenues from our trading activities during the three months ended September 30, 2021 included significant unrealized losses from market price changes of Alzamend's common stock. Unrealized gain and losses have caused, and will continue to cause, significant volatility in our periodic earnings.

    At September 30, 2021, the fair value of Alzamend's common stock was $3.08, the shares' closing price that day. Based upon the fair value of Alzamend common stock at September 30, 2021, during the three months ended September 30, 2021, we recorded an unrealized loss of $27.4 million related to our investment in Alzamend common stock. During the three months ended September 30, 2021, we recorded an unrealized loss on our investment in warrants of Alzamend of $6.0 million. Our investment in Alzamend will be revalued on each balance sheet date.

    Gross margins

    Gross margins were negative $36.0 million or 117.1% for the three months ended September 30, 2021 compared to 35.3% for the three months ended September 30, 2020. Our gross margins have typically ranged between 33% and 37%, with slight variations depending on the overall composition of our revenue.

    Our gross margins during the three months ended September 30, 2021, were impacted by the unfavorable margins from our lending and trading activities. Excluding the effects of margin from our lending and trading activities, our adjusted gross margins for the three months ended September 30, 2021, would have been 34.7%, consistent with our historical range.

    Operating expenses

    Operating expenses increased to $13.8 million for the three months ended September 30, 2021, representing an increase of $10.2 million compared to $3.6 million for the three months ended September 30, 2020.

    The increase in operating expenses from the three months ended September 30, 2020 is attributable to the following:

    • Research and development expenses increased by $55,000 to $524,000 for the three months ended September 30, 2021, from $469,000 for the three months ended September 30, 2020. The increase in research and development expenses is due to costs incurred at GWW related to the development of products for defense applications.
    • Selling and marketing expenses were $2.0 million for the three months ended September 30, 2021, compared to $260,000 for the three months ended September 30, 2020, an increase of $1.7 million, or 667%. The increase was the result of greater personnel costs directly attributed to an increase in sales and marketing personnel and consultants primarily at Ault Alliance related to digital marketing and digital learning. The increase is also attributable to costs incurred at TurnOnGreen to grow our selling and marketing infrastructure related to our electric vehicle charger products.
    • General and administrative expenses were $11.3 million for the three months ended September 30, 2021, compared to $2.8 million for the three months ended September 30, 2020, an increase of $8.5 million or 298%. General and administrative expenses increased from the comparative prior period, mainly due to:
      • non-cash stock compensation costs of $4.1 million;
      • the accrual of an $859,000 performance bonus related to realized gains on trading activities during the period;
      • general and administrative costs of $385,000 from Relec, which was acquired on November 30, 2020;
      • increased costs related to our Michigan data center, operated by Alliance Cloud Services; and
      • higher consulting, audit, legal and insurance costs.

    The Company's Chief Financial Officer, Kenneth S. Cragun, said, "The financial results for the third quarter of 2021 reflected significant unrealized losses from market price changes of our investments. At the end of each quarter, we value our investments in certain companies based on the trading price of their stock, which has resulted in significant volatility in both revenue and operating results over the last two quarters. On a year-to-date basis, however, we did see significant revenue growth and improved operating results, with revenue up 167% over the prior year period and net income of $1.3 million compared to a net loss of $24.7 million for the nine months ended September 30, 2020. During the third quarter of 2021, we were able to make significant investments in our BitNile subsidiary and ended the quarter with $20.4 million in Bitcoin mining equipment, which will contribute to both revenue growth and improved profitability in future periods."

    The Company's Founder and Executive Chairman, Milton "Todd" Ault, III said, "In spite of the volatility of our quarterly financial results, we believe the future prospects for the Company are extremely promising. Quite simply, we are in a strong financial position, and we are investing for the future. We have grown assets to $225.7 million and have announced key investments in our Michigan data center and Bitcoin mining equipment. We would like to acknowledge our GWW defense team as during the third quarter of 2021 they grew revenues by 47% compared to the prior third fiscal quarter. As a holding company, we have made investments in the sectors of Bitcoin mining, data center operations, defense, electric vehicle chargers, power electronic businesses, lending and investment platform, and we continue to believe the road ahead is bright."

    Reminder - Company to hold special stockholder conference call and webcast for major corporate announcement

    As previously announced, on Monday, November 22, 2021 at 6:00 a.m. Pacific time, the Company's Executive Chairman, Milton "Todd" Ault, III and its CEO, William Horne will be hosting a conference call and webcast to discuss a major corporate announcement along with the financial performance and outlook of the Company and its subsidiaries. Joining Mr. Ault and Mr. Horne will be Kenneth Cragun, the Company's CFO. The Company encourages all stockholders to attend this meeting, if possible.

    Stockholders, investors and interested parties who desire to participate in the webcast must use the following link to register prior to 6:00 a.m. Pacific time on November 22, 2021:

    https://zoom.us/webinar/register/WN_a3zZ_BmyRrK4fBqAc6-hvg

    For more information on Ault Global Holdings and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company's public filings and press releases available under the Investor Relations section at www.AultGlobal.com or available at www.sec.gov.

    About Ault Global Holdings, Inc.

    Ault Global Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, the Company provides mission-critical products that support a diverse range of industries, including defense/aerospace, industrial, automotive, telecommunications, medical/biopharma, and textiles. In addition, the Company extends credit to select entrepreneurial businesses through a licensed lending subsidiary. Ault Global Holding's headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; www.AultGlobal.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company's business and financial results are included in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Forms 10-K, 10-Q, and 8-K. All filings are available at www.sec.gov and on the Company's website at www.AultGlobal.com.

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    September 30,

    December 31,

     

    2021

     

    2020

    ASSETS

     

    CURRENT ASSETS

     

     

     

    Cash and cash equivalents

    $

    105,391,000

    $

    18,680,000

    Marketable equity securities

     

    30,172,000

     

     

    2,563,000

    Accounts receivable

     

    4,730,000

     

    3,852,000

    Accounts and other receivable, related party

     

    1,196,000

     

     

    1,196,000

    Accrued revenue

     

    1,594,000

     

    1,696,000

    Inventories

     

    2,900,000

     

     

    3,374,000

    Prepaid expenses and other current assets

     

    5,373,000

     

    2,988,000

    TOTAL CURRENT ASSETS

     

    151,356,000

     

     

    34,349,000

     

    Intangible assets, net

     

    4,175,000

     

     

    4,390,000

    Goodwill

     

    9,589,000

     

    9,646,000

    Property and equipment, net

     

    7,262,000

     

     

    2,123,000

    Right-of-use assets

     

    4,605,000

     

    4,318,000

    Investment in promissory notes, related parties

     

    13,913,000

     

     

    10,668,000

    Investments in common stock and warrants, related parties

     

    60,355,000

     

    6,139,000

    Investments in debt and equity securities

     

    4,013,000

     

     

    262,000

    Investment in limited partnership

     

    1,869,000

     

    1,869,000

    Loans receivable

     

    572,000

     

     

    750,000

    Other investments, related parties

     

    788,000

     

    803,000

    Other assets

     

    604,000

     

     

    326,000

    TOTAL ASSETS

    $

    259,101,000

    $

    75,643,000

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES

    Accounts payable and accrued expenses

    $

    7,784,000

     

    $

    10,579,000

    Accounts payable and accrued expenses, related party

     

    —

     

    36,000

    Operating lease liability, current

     

    876,000

     

     

    524,000

    Revolving credit facility

     

    103,000

     

    125,000

    Notes payable, net

     

    1,808,000

     

     

    4,048,000

    Notes payable, related parties

     

    —

     

    188,000

    Convertible notes payable, related party

     

    —

     

     

    400,000

    Warrant liability

     

    4,580,000

     

    4,192,000

    Income taxes payable

     

    2,770,000

     

     

    —

    Other current liabilities

     

    5,572,000

     

     

    1,790,000

    TOTAL CURRENT LIABILITIES

    $

    23,493,000

    $

    21,882,000

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

    (Unaudited)

    September 30,

    December 31,

     

    2021

     

     

    2020

     

    LONG TERM LIABILITIES

    Operating lease liability, non-current

     

    3,792,000

     

     

     

    3,855,000

     

    Notes payable

     

    —

     

     

    336,000

     

    Notes payable, related parties

     

    —

     

     

     

    52,000

     

    Convertible notes payable

     

    427,000

     

     

    386,000

     

     

    TOTAL LIABILITIES

     

    27,712,000

     

     

    26,511,000

     

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

    Series A Convertible Preferred Stock, $25.00 stated value per share,

     

    —

     

     

    —

     

    $0.001 par value – 1,000,000 shares authorized; 7,040 shares

    issued and outstanding at September 30, 2021 and December 31, 2020

    (redemption amount and liquidation preference of $176,000

    as of September 30, 2021 and December 31, 2020)

    Series B Convertible Preferred Stock, $10 stated value per share,

     

    —

     

     

     

    —

     

    $0.001 par value – 500,000 shares authorized; 125,000 shares issued

     

     

     

    and outstanding at September 30, 2021 and December 31, 2020 (liquidation

     

     

     

    preference of $1,250,000 at September 30, 2021 and December 31, 2020)

     

     

     

    Class A Common Stock, $0.001 par value – 500,000,000 shares authorized;

     

    56,000

     

     

    28,000

     

    56,159,963 and 27,753,562 shares issued and outstanding at September 30,

    2021 and December 31, 2020, respectively

    Class B Common Stock, $0.001 par value – 25,000,000 shares authorized;

     

    —

     

     

     

    —

     

    nil shares issued and outstanding at September 30, 2021 and December 31,

    2020

     

     

     

    Additional paid-in capital

     

    311,760,000

     

     

    171,397,000

     

    Accumulated deficit

     

    (77,190,000

    )

     

     

    (121,397,000

    )

    Accumulated other comprehensive gain (loss)

     

    (4,601,000

    )

     

    (1,718,000

    )

    TOTAL AULT GLOBAL HOLDINGS STOCKHOLDERS' EQUITY

     

    230,025,000

     

     

     

    48,310,000

     

     

    Non-controlling interest

     

    1,364,000

     

     

     

    822,000

     

     

    TOTAL STOCKHOLDERS' EQUITY

     

    231,389,000

     

     

     

    49,132,000

     

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

    $

    259,101,000

     

     

    $

    75,643,000

     

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) (Unaudited)

    For the Three Months Ended

    For the Nine Months Ended

    September 30,

    September 30,

     

    2021

     

     

     

    2020

     

     

     

    2021

     

     

     

    2020

     

    Revenue

    $

    8,564,000

     

     

    $

    5,435,000

     

     

    $

    16,469,000

     

     

    $

    11,004,000

     

    Revenue, cryptocurrency mining

     

    291,000

     

     

    —

     

     

    421,000

     

     

    —

     

    Revenue, lending and trading activities

     

    53,274,000

     

     

     

    (34,000

    )

     

     

    58,485,000

     

     

     

    2,000

     

    Total revenue

     

    62,129,000

     

     

    5,401,000

     

     

    75,375,000

     

     

    11,006,000

     

    Cost of revenue

     

    6,278,000

     

     

     

    3,496,000

     

     

     

    11,386,000

     

     

     

    7,349,000

     

    Gross profit

     

    55,851,000

     

     

    1,905,000

     

     

    63,989,000

     

     

    3,657,000

     

     

    Operating expenses

     

     

     

     

     

     

     

    Research and development

     

    531,000

     

     

    462,000

     

     

    1,133,000

     

     

    903,000

     

    Selling and marketing

     

    1,505,000

     

     

     

    295,000

     

     

     

    2,747,000

     

     

     

    633,000

     

    General and administrative

     

    7,992,000

     

     

    2,918,000

     

     

    13,084,000

     

     

    5,821,000

     

    Provision for credit losses

     

    —

     

     

     

    (1,000,000

    )

     

     

    —

     

     

     

    —

     

    Total operating expenses

     

    10,028,000

     

     

    2,675,000

     

     

    16,964,000

     

     

    7,357,000

     

    Income (loss) from continuing operations

     

    45,823,000

     

     

     

    (770,000

    )

     

     

    47,025,000

     

     

     

    (3,700,000

    )

    Other income (expenses)

    Interest income

     

    14,000

     

     

     

    36,000

     

     

     

    51,000

     

     

     

    36,000

     

    Interest expense

     

    (22,000

    )

     

    (963,000

    )

     

    (337,000

    )

     

    (2,049,000

    )

    Change in fair value of marketable equity securities

     

    (1,915,000

    )

     

     

    337,000

     

     

     

    45,000

     

     

     

    (29,000

    )

    Realized gain on marketable securities

     

    —

     

     

    —

     

     

    397,000

     

     

    —

     

    Gain (loss) on extinguishment of debt

     

    447,000

     

     

     

    (12,000

    )

     

     

    929,000

     

     

     

    (475,000

    )

    Change in fair value of warrant liability

     

    290,000

     

     

    (10,000

    )

     

    (388,000

    )

     

    (6,000

    )

    Total other income (expenses), net

     

    (1,186,000

    )

     

     

    (612,000

    )

     

     

    697,000

     

     

     

    (2,523,000

    )

    Income (loss) from continuing operations before income taxes

     

    44,637,000

     

     

     

    (1,382,000

    )

     

    47,722,000

     

     

    (6,223,000

    )

    Income tax (expense) benefit

     

    (3,504,000

    )

     

     

    6,000

     

     

     

    (3,510,000

    )

     

     

    12,000

     

    Net income (loss) from continuing operations

     

    41,133,000

     

     

    (1,376,000

    )

     

    44,212,000

     

     

    (6,211,000

    )

    Net loss from discontinued operations, net of taxes

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (1,698,000

    )

    Net income (loss)

     

    41,133,000

     

     

    (1,376,000

    )

     

    44,212,000

     

     

    (7,909,000

    )

    Net loss attributable to non-controlling interest

     

    1,083,000

     

     

     

    —

     

     

     

    3,000

     

     

     

    —

     

    Net income (loss) attributable to Ault Global Holdings

     

    42,216,000

     

     

    (1,376,000

    )

     

    44,215,000

     

     

    (7,909,000

    )

    Preferred dividends

     

    (4,000

    )

     

     

    (3,000

    )

     

     

    (9,000

    )

     

     

    (7,000

    )

    Net income (loss) available to common stockholders

    $

    42,212,000

     

    $

    (1,379,000

    )

    $

    44,206,000

     

    $

    (7,916,000

    )

     

     

     

     

     

     

     

     

    Basic net income (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.82

     

    $

    (0.24

    )

    $

    0.97

     

    $

    (1.20

    )

    Discontinued operations

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (0.33

    )

    Net income (loss) per common share

    $

    0.82

     

    $

    (0.24

    )

    $

    0.97

     

    $

    (1.52

    )

     

     

     

     

     

     

     

     

    Diluted net income (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.79

     

    $

    (0.24

    )

    $

    0.91

     

    $

    (1.20

    )

    Discontinued operations

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (0.33

    )

    Net income (loss) per common share

    $

    0.79

     

    $

    (0.24

    )

    $

    0.91

     

    $

    (1.52

    )

    Weighted average basic common shares outstanding

     

    50,783,000

     

     

     

    5,864,000

     

     

     

    45,052,000

     

     

     

    5,199,000

     

    Weighted average diluted common shares outstanding

     

    52,780,000

     

     

    5,864,000

     

     

    47,574,000

     

     

    5,199,000

     

     

     

     

     

     

     

     

     

    Comprehensive income (loss)

     

     

     

     

     

     

     

    Net income (loss) available to common stockholders

    $

    42,212,000

     

    $

    (1,379,000

    )

    $

    44,206,000

     

    $

    (7,916,000

    )

    Other comprehensive income (loss)

     

     

     

     

     

     

     

    Foreign currency translation adjustment

     

    134,000

     

     

    97,000

     

     

    41,000

     

     

    (51,000

    )

    Net unrealized gain (loss) on derivative securities of related party

     

    (5,893,000

    )

     

     

    761,000

     

     

     

    (2,924,000

    )

     

     

    (481,000

    )

    Other comprehensive income (loss)

     

    (5,759,000

    )

     

    858,000

     

     

    (2,883,000

    )

     

    (532,000

    )

    Total comprehensive income (loss)

    $

    36,453,000

     

     

    $

    (521,000

    )

     

    $

    41,323,000

     

     

    $

    (8,448,000

    )

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

    For the Nine Months Ended September 30,

     

    2021

     

     

    2020

     

     

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    44,212,000

     

    $

    (7,909,000

    )

    Less: Net loss from discontinued operations

     

    —

     

     

     

    (1,698,000

    )

    Net income (loss) from continuing operations

     

    44,212,000

     

     

    (6,211,000

    )

    Adjustments to reconcile net income (loss) to net cash used in

    operating activities:

     

     

    Depreciation

     

    446,000

     

     

    260,000

     

    Amortization

     

    191,000

     

     

     

    167,000

     

    Amortization of right-of-use assets

     

    441,000

     

     

    247,000

     

    Amortization, related party

     

    15,000

     

     

     

    —

     

    Interest expense – debt discount

     

    40,000

     

     

    908,000

     

    Gain on extinguishment of debt

     

    (929,000

    )

     

     

    —

     

    Change in fair value of warrant liability

     

    (290,000

    )

     

    10,000

     

    Accretion of original issue discount on notes receivable – related party

     

    (4,000

    )

     

     

    15,000

     

    Accretion of original issue discount on notes receivable

     

    (955,000

    )

     

    (4,000

    )

    Increase in accrued interest on notes receivable – related party

     

    (1,000

    )

     

     

    —

     

    Stock-based compensation

     

    584,000

     

     

    143,000

     

    Realized losses on other investments

     

    —

     

     

     

    28,000

     

    Realized gains on sale of marketable securities

     

    (12,283,000

    )

     

    (15,000

    )

    Unrealized gains on marketable equity securities

     

    (3,483,000

    )

     

     

    (52,000

    )

    Unrealized (gains) losses on equity securities – related party

     

    (39,852,000

    )

     

    65,000

     

    Unrealized (gains) losses on equity securities

     

    (1,224,000

    )

     

     

    73,000

     

    Changes in operating assets and liabilities:

     

     

     

    Marketable equity securities

     

    (9,616,000

    )

     

    —

     

    Accounts receivable

     

    (887,000

    )

     

     

    199,000

     

    Accrued revenue

     

    78,000

     

     

    34,000

     

    Inventories

     

    485,000

     

     

     

    (35,000

    )

    Prepaid expenses and other current assets

     

    (2,537,000

    )

     

    181,000

     

    Other assets

     

    (246,000

    )

     

     

    (39,000

    )

    Accounts payable and accrued expenses

     

    (2,651,000

    )

     

    1,365,000

     

    Accounts payable, related parties

     

    (36,000

    )

     

     

    (24,000

    )

    Income taxes payable

     

    2,770,000

     

     

     

    Other current liabilities

     

    4,472,000

     

     

    660,000

     

    Lease liabilities

     

    (439,000

    )

     

     

    (234,000

    )

    Net cash used in continuing operating activities

     

    (21,699,000

    )

     

    (2,259,000

    )

    Net cash provided by discontinued operating activities

     

    —

     

     

     

    1,000

     

    Net cash used in operating activities

     

    (21,699,000

    )

     

    (2,258,000

    )

     

     

     

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (5,590,000

    )

     

    (190,000

    )

    Investment in promissory notes, related parties

     

    (4,040,000

    )

     

     

    (199,000

    )

    Investments in common stock and warrants, related parties

     

    (16,483,000

    )

     

    (10,000

    )

    Investment in real property, related party

     

    (2,670,000

    )

     

     

    —

     

    Proceeds from sale of investment in real property, related party

     

    2,670,000

     

     

    —

     

    Purchase of marketable equity securities

     

    —

     

     

     

    —

     

    Sales of marketable equity securities

     

    430,000

     

     

    110,000

     

    Proceeds from loans receivable

     

    —

     

     

     

    140,000

     

    Investments in debt and equity securities

     

    (4,054,000

    )

     

    (3,000

    )

    Net cash used in investing activities

    $

    (29,737,000

    )

     

    $

    (152,000

    )

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (continued)

    For the Nine Months Ended September 30,

     

    2021

     

     

    2020

     

     

    Cash flows from financing activities:

     

     

     

    Gross proceeds from sales of common stock

    $

    144,044,000

     

    $

    —

     

    Financing cost in connection with sales of equity securities

     

    (4,541,000

    )

     

     

    —

     

    Proceeds from convertible notes payable

     

    —

     

     

    100,000

     

    Proceeds from notes payable

     

    500,000

     

     

     

    3,148,000

     

    Proceeds from short-term advances – related party

     

    —

     

     

    604,000

     

    Payments on short-term advances – related party

     

    —

     

     

     

    (98,000

    )

    Payments on notes payable

     

    (1,917,000

    )

     

    (186,000

    )

    Payments on advances on future receipts

     

    -

     

     

     

    (20,000

    )

    Payments of preferred dividends

     

    (9,000

    )

     

    (7,000

    )

    Payments on revolving credit facilities, net

     

    (23,000

    )

     

     

    68,000

     

     

     

    Net cash provided by financing activities

     

    138,054,000

     

     

    3,609,000

     

     

     

     

     

    Effect of exchange rate changes on cash and cash equivalents

     

    93,000

     

     

     

    9,000

     

     

    Net increase in cash and cash equivalents

     

    86,711,000

     

     

     

    1,208,000

     

     

    Cash and cash equivalents at beginning of period

     

    18,680,000

     

     

     

    483,000

     

     

     

    Cash and cash equivalents at end of period

    $

    105,391,000

     

    $

    1,691,000

     

     

     

     

     

    Supplemental disclosures of cash flow information:

    Cash paid during the period for interest

    $

    658,000

     

     

    $

    71,000

     

     

    Non-cash investing and financing activities:

     

     

     

    Cancellation of convertible notes payable into shares of common stock

    $

    —

     

    $

    2,689,000

     

    Cancellation of notes payable into shares of common stock

    $

    449,000

     

     

    $

    —

     

    Payment of accounts payable with digital currency

    $

    119,000

     

    $

    —

     

    Issuance of common stock in payment of liability

    $

    —

     

     

    $

    229,000

     

    Cancellation of short-term advances, related party into shares

    of common stock

    $

    —

     

    $

    740,000

     

    Issuance of notes payable and convertible notes payable in

     

     

     

    payment of accrued expenses

    $

    —

     

     

    $

    420,000

     

    Conversion of debt and equity securities to marketable securities

    $

    2,656,000

     

    $

    —

     

    Conversion of loans to debt and equity securities

    $

    150,000

     

     

    $

    —

     

    Conversion of convertible notes payable, related party into shares

    of common stock

    $

    400,000

     

     

    $

    —

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005751/en/

    Get the next $ALZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALZN
    $DPW

    CompanyDatePrice TargetRatingAnalyst
    Alzamend Neuro Inc.
    $ALZN
    10/1/2021$8.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALZN
    $DPW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Katzoff David J bought $5,048 worth of shares (5,000 units at $1.01), increasing direct ownership by 926% to 5,540 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/24/25 7:30:07 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ault Milton C Iii sold $6,196 worth of shares (1,224 units at $5.06), decreasing direct ownership by 0.59% to 1,843 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      5/14/25 5:00:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    SEC Filings

    See more
    • SEC Form 144 filed by Alzamend Neuro Inc.

      144 - Alzamend Neuro, Inc. (0001677077) (Subject)

      5/9/25 7:49:16 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

      5/8/25 4:30:42 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

      4/25/25 4:30:45 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

      Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

      10/1/21 7:11:54 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

      ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the "Agreement") with a sophisticated investor (the "Investor"), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Conver

      6/16/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows th

      5/29/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follow

      5/19/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Leadership Updates

    Live Leadership Updates

    See more
    • Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

      Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

      4/4/22 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ault Global Holdings Announces Adtech Pharma, Inc., an Innovative Biotech, Appoints Jodi Brichan to Its Board of Directors

      Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), announced that Adtech Pharma, Inc. ("Adtech"), has appointed Jodi Brichan, to its Board of Directors. Ms. Brichan was a member of the board of directors of the Company until August 13, 2021. In June of 2021, the Company entered a securities purchase agreement (the "Agreement") with Adtech that granted the Company the right to acquire up to 40% of the current equity in Adtech, an innovative biotechnology company, for $3 million. The right to appoint Ms. Brichan was provided for in the Agreement. The investment in Adtech was made through Digital Power Lending, LLC, a wholly owned subsidiary of the Company. J

      9/27/21 6:30:00 AM ET
      $DPW
      Industrial Machinery/Components
      Capital Goods
    • Ault Global Holdings, Inc. Announces Results of Annual Meeting of Stockholders

      Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company ("AGH," or the "Company"), announced the results of the Company's 2021 Annual Meeting of Stockholders (the "Meeting"), which was held today, August 13, 2021, at 9:00 a.m. PT, and at which time the seven proposals voted upon, as set forth in the Company's Definitive Proxy Statement dated June 7, 2021 (the "Proxy Statement"), were approved by the stockholders. At the Meeting, the stockholders voted upon and approved the following proposals as described in the Proxy Statement: Election of the eight (8) director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders; Ratificatio

      8/13/21 4:15:00 PM ET
      $DPW
      Industrial Machinery/Components
      Capital Goods